[{"address1": "175 Innovation Boulevard", "city": "Wilmington", "state": "DE", "zip": "19805", "country": "United States", "phone": "302 467 1280", "website": "https://preludetx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.", "fullTimeEmployees": 128, "companyOfficers": [{"maxAge": 1, "name": "Dr. Krishna  Vaddi D.V.M., Ph.D.", "age": 57, "title": "Founder, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 905916, "exercisedValue": 0, "unexercisedValue": 2692674}, {"maxAge": 1, "name": "Dr. Edna  Huang M.D.", "age": 50, "title": "President & Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 865629, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Lindsey  Trickett", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michele  Porreca M.B.A.", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew P. Combs Ph.D.", "age": 56, "title": "Executive VP & Chief Chemistry Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 562461, "exercisedValue": 0, "unexercisedValue": 399432}, {"maxAge": 1, "name": "Mr. Naveen  Babbar Ph.D.", "title": "Senior Vice President of Translation Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William B. Novotny M.D.", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Wan-Jen  Hong M.D.", "age": 44, "title": "Senior Vice President of Clinical Development", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1714348800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.84, "open": 3.84, "dayLow": 3.56, "dayHigh": 3.86, "regularMarketPreviousClose": 3.84, "regularMarketOpen": 3.84, "regularMarketDayLow": 3.56, "regularMarketDayHigh": 3.86, "beta": 1.498, "forwardPE": -2.3271604, "volume": 47216, "regularMarketVolume": 47216, "averageVolume": 68903, "averageVolume10days": 54460, "averageDailyVolume10Day": 54460, "bid": 3.68, "ask": 3.98, "bidSize": 100, "askSize": 100, "marketCap": 207050656, "fiftyTwoWeekLow": 1.66, "fiftyTwoWeekHigh": 6.89, "fiftyDayAverage": 4.4242, "twoHundredDayAverage": 3.61505, "currency": "USD", "enterpriseValue": -9098181, "floatShares": 13627882, "sharesOutstanding": 42070300, "sharesShort": 604040, "sharesShortPriorMonth": 643171, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.011, "heldPercentInsiders": 0.0904, "heldPercentInstitutions": 0.96261, "shortRatio": 14.72, "shortPercentOfFloat": 0.0454, "impliedSharesOutstanding": 54920600, "bookValue": 4.32, "priceToBook": 0.87268513, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -121832000, "trailingEps": -2.02, "forwardEps": -1.62, "pegRatio": -0.07, "enterpriseToEbitda": 0.069, "52WeekChange": -0.4072327, "SandP52WeekChange": 0.23099434, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "PRLD", "underlyingSymbol": "PRLD", "shortName": "Prelude Therapeutics Incorporat", "longName": "Prelude Therapeutics Incorporated", "firstTradeDateEpochUtc": 1601040600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b4d5f445-4c0f-32e5-9fdb-a86b330519d9", "messageBoardId": "finmb_373775974", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.77, "targetHighPrice": 10.0, "targetLowPrice": 3.0, "targetMeanPrice": 5.8, "targetMedianPrice": 5.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 5, "totalCash": 232935008, "totalCashPerShare": 4.243, "ebitda": -131108000, "totalDebt": 16888000, "quickRatio": 10.671, "currentRatio": 10.792, "debtToEquity": 7.123, "returnOnAssets": -0.33191, "returnOnEquity": -0.56334996, "freeCashflow": -58925124, "operatingCashflow": -107063000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-01"}]